CClinicalTrials.gg
RecruitingNCT07360418SCANXUpdated Feb 10, 2026

Evaluating the Durability of Closure for Diabetic Foot Ulcers Following a Randomized, Controlled, Modified Platform Trial.

An observational study in Diabetic Foot Ulcers (DFU), Foot Ulcer Chronic and Ulcer, sponsored by Applied Biologics, LLC. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-10.

Sponsored by Applied Biologics, LLC · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
50
Ages
18 Years and older
Sex
All
01

Study summary

Prospective long-term follow-up on durability of closure evaluated by photographic and thermal scanning.

Read the detailed description

This study is a follow-up durability trial from the CAMPX randomized controlled clinical trial. Only subjects who achieved complete closure at 12 weeks in the CAMPX trial will be evaluated. After signing the IRB-approved informed consent form, the subject will receive instruction on the BlueDrop® OneStep Foot Scanner™. In addition, written instructions on use will be provided. Subjects that are unable to use the scale will be asked to answer a questionnaire at 3, 6, 9, and 12 months after signing the consent form..

02

Conditions studied

  • Diabetic Foot Ulcers (DFU)
  • Foot Ulcer Chronic
  • Ulcer
  • Diabetic Foot Ulcer

Keywords

  • CAMPX
  • CAMP
  • Foot Ulcer
  • diabetic foot ulcer
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Sampling method
Non-probability sample

Study population

The study population will be drawn from diabetic subjects who have previously completed the CAMPX trial and achieved complete closure.

Inclusion criteria

  • The potential subject must have participated in the CAMPX trial and achieved complete closure by the 12-week endpoint.

Exclusion criteria

Exclusion Criteria:

  • The potential subject did not participate in the CAMPX trial.
  • The potential subject participated in the CAMPX trial and did not achieve complete closure.
04

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
50 participants (estimated)
Patient registry
No

Groups and cohorts

  • OneStep Foot Scanner

    This study is a follow-up durability trial from the CAMPX randomized controlled clinical trial. Only subjects who achieved complete closure at 12 weeks in the CAMPX trial will be evaluated. After signing the IRB-approved informed consent form, the subject will receive instruction on the BlueDrop® OneStep Foot Scanner™. In addition, written instructions on use will be provided. Subjects that are unable to use the scale will be asked to answer a questionnaire at 3, 6, 9, and 12 months after signing the consent form.

    Other: Blue Drop Foot Scanner

Interventions

  • OtherBlue Drop Foot Scanner

    Subjects with eligible wound will receive a BlueDrop® OneStep Foot Scanner™. They are instructed to step on the scale each morning. The Bluetooth technology transmits a photograph and thermal image to the central monitoring nurse at BlueDrop®. All information transmitted is compliant with HIPPA regulations. Subjects that are unable to use the scale will receive a phone call at months 3,6, 9 and 12 months to determine if the foot has remained closed.

05

What researchers measure

Primary outcomes

  1. Rate of Recurrence

    To demonstrate durability of closure (rate of recurrence) of subjects with a closed diabetic foot ulcer during the CAMPX clinical trial comparing subjects treated with Single Layer Amniotic Membrane (SLAM) plus standard of care (SOC) to subjects treated with SOC alone.

    Time frame: 52 weeks

Secondary outcomes

  1. Virtual Long-Term Follow Up

    To evaluate the effectiveness of virtual clinical trial technology in the conduct of a long-term follow up trial.

    Time frame: 52 weeks

06

Study locations

1 of 1 sites recruiting
  • Detroit Foot and Ankle
    Clinton Township, Michigan 48038, United States
    • Lina Barman · Contact
    Recruiting
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT07360418
Lead sponsor
Applied Biologics, LLC
Collaborators
Serena Group
Responsible party
Sponsor
First posted
Jan 22, 2026
Start date
Oct 16, 2025
Primary completion
Oct 2027 (estimated)
Completion
Oct 2027 (estimated)
Last update
Feb 10, 2026

Study contacts

Bennett Sarver
Contact
info@serenagroups.com
1-833-865-6300
Thomas Serena, MD
Contact
info@serenagroups.com
1-833-865-6300

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion